A large-scale study conducted by researchers at Cardiff University says that type 2 diabetes patients live longer than people without the disease thanks to surprising benefits of their medication, metformin, which could be expanded for use in non-diabetics.
Murmurs of metformin's attributes had been circulating within the scientific community, and the findings of the Cardiff study not only build on its benefits but are of particular interest due to the massive sample size of 180,000 participants.
Researchers compared survival rates of type 2 diabetes patients taking metformin, a first-line therapy, with those of patients on a less-prescribed diabetes drug called sulphonylurea, known for undesirable side effects such as weight gain and hypoglycemia.
"What we found was illuminating," said lead author Professor Craig Currie from Cardiff University's School of Medicine.
According to Dr. Currie, patients undergoing metformin treatment exhibited small yet statistically important survival increases by comparison to non-diabetics.
As for those treated with sulphonylureas, their rate of survival was consistently reduced when compared to that of non-diabetics. ...more